BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QLM3003 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QLM3003\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06880276-1468@assetmemo.bio
DTSTAMP:20261121T004454Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:QLM3003: Phase 3 readout est. (NCT06880276)
DESCRIPTION:QLM3003\, phase 3\, Atopic Dermatitis.\nStudy: Efficacy and Saf
 ety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic
  Dermatitis\nEstimated primary completion: March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/qlm3003#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06880276
URL:https://assetmemo.bio/drug/qlm3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
